ReviewFrontiers in bioengineering and biotechnology2025
Advances in materials science for ocular diseases induced by cardiovascular risk factors.
Review in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular risk factors such as hypertension, hyperlipidemia, and hyperglycemia are closely associated with ocular diseases including glaucoma, diabetic retinopathy, and dry eye syndrome. These conditions are characterized by microvascular damage, hemodynamic alterations, and pathological neovascularization, ultimately leading to significant visual impairment. Traditional treatments often suffer from limitations, such as invasiveness and poor target specificity, highlighting the urgent need for innovative therapeutic approaches. Recent advancements in biomaterials have substantially improved therapeutic efficacy, particularly in the areas of targeted drug delivery, smart sensors, and tissue repair. Smart sensors like contact lenses enable continuous monitoring of intraocular pressure, enhancing glaucoma management. Nanotechnology and drug delivery systems improve drug targeting and bioavailability, enhancing anti-angiogenic therapies. Additionally, biocompatible materials and nanomaterials have shown promise in promoting retinal and optic nerve repair, facilitating neural regeneration and reducing aberrant neovascularization. Despite ongoing challenges, the rapid evolution of materials science holds transformative potential for developing more effective and personalized treatments for ocular diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.